Drug Profile
Research programme: microRNA-targeted therapeutics - Regulus/Rosetta
Latest Information Update: 11 Feb 2011
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals; Rosetta Genomics
- Developer Regulus Therapeutics; Rosetta Genomics
- Class Antisense oligonucleotides; Gene therapies
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 16 Nov 2007 In vivo development of microRNA candidates has been initiated
- 22 Feb 2006 Preclinical trials in Liver cancer in Israel (unspecified route)
- 22 Feb 2006 Preclinical trials in Liver cancer in USA (unspecified route)